European Medicines Agency (EMA): * EMA RECOMMENDS APPROVAL FOR USE OF ROACTEMRA IN ADULTS WITH SEVERE COVID-19: 06/12/2021
* SAFETY PROFILE OF MEDICINE FAVOURABLE IN THOSE RECEIVING TREATMENT WITH CORTICOSTEROIDS, CONCLUDED MEDICINE'S BENEFITS GREATER THAN RISKS FOR THESE PATIENTS * RECOMMENDED EXTENDING TOCILIZUMAB INDICATION FOR TREATMENT OF ADULTS WITH COVID ON SYSTEMIC TREATMENT WITH CORTICOSTEROIDS AND NEED OXYGEN SUPPORT Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}